HER2 Expression Detection in Breast Cancer Using 99mTc-NM-02
Status:
Recruiting
Trial end date:
2021-04-30
Target enrollment:
Participant gender:
Summary
A 99mTc-labeled anti-HER2-sdAb (99mTc-NM-02) will be developed for SPECT/CT assessment of
HER2 expression in breast cancer patients. Its safety, radiation dosimetry and
biodistribution, and the relationship between tumor uptake and HER2 immunohistochemistry
results will be investigated.
Phase:
Early Phase 1
Details
Lead Sponsor:
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine